Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after chemotherapy.
The drug slows or stops tumor growth by inhibiting an enzyme that helps the DNA inside cancerous cells repair itself.
More than 22,000 women will be diagnosed with these three cancers in 2017 and more than 14,000 will die, according to estimates from the National Cancer Institutes.
Tesaro expects Zejula to hit the market in late April, according to a company news release.
More articles on supply chain:
How Centura Health eliminated waste and boosted efficiency in its supply chain
6 notable device recalls in 2016
Insys Therapeutics receives DEA approval for synthetic marijuana drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
